ReviewProceedings of the American Thoracic Society2007
Endpoints for clinical trials in young children with cystic fibrosis.
Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 75 citations in OpenAlex.
- Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.American journal of respiratory and critical care medicine · 2018Trial
- Trial
- Deep Learning Approaches for Quantifying Ventilation Defects in Hyperpolarized Gas Magnetic Resonance Imaging of the Lung: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Could automated analysis of chest X-rays detect early bronchiectasis in children?European journal of pediatrics · 2021Article
- Current state of the art MRI for the longitudinal assessment of cystic fibrosis.Journal of magnetic resonance imaging : JMRI · 2020Review
- Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial.Contemporary clinical trials · 2019Article
- Ultrashort Echo-Time Magnetic Resonance Imaging Is a Sensitive Method for the Evaluation of Early Cystic Fibrosis Lung Disease.Annals of the American Thoracic Society · 2016Observational
- The Evolution of Cystic Fibrosis Care.Chest · 2015Review
- Article
- Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Annals of the American Thoracic Society · 2014Review
- Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease.American journal of respiratory cell and molecular biology · 2013Article
- Article
- Nasal versus oronasal raised volume forced expirations in infants--a real physiologic challenge.Pediatric pulmonology · 2012Article
- Article
- Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.American journal of respiratory and critical care medicine · 2012Article
- Computed tomography score and pulmonary function in infants with chronic lung disease of infancy.The European respiratory journal · 2011Article
- Endpoints in respiratory diseases.European journal of clinical pharmacology · 2011Review
- Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.American journal of respiratory and critical care medicine · 2010Article
- Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.Pediatric pulmonology · 2010Article
- The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI?Pediatric radiology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lung disease in very young children with CF was hampered by a lack of reproducible measures of lung function or lung pathology. Over the past 10 years, significant progress has led to physiologic, anatomic, and bronchoscopic measures that may serve as endpoints for future intervention trials. These endpoints include infant and preschool lung function testing, computed tomography of the chest, and bronchoalveolar lavage markers of inflammation and infection. Much progress has occurred in standardizing lung function testing, which is essential for multicenter collaboration. Pulmonary exacerbation has the potential to serve as a clinical endpoint; however, there is currently no standardized definition in children with CF younger than 6 years. Further development of these outcomes measures will enable clinical trials in the youngest CF population with the objective of improving long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.